# ASCL2

## Overview
The ASCL2 gene encodes the achaete-scute family bHLH transcription factor 2, a basic helix-loop-helix (bHLH) transcription factor that plays a pivotal role in the regulation of stem cell maintenance and differentiation, particularly within the intestinal epithelium. This protein is a key component of the Wnt signaling pathway, acting as a master regulator of crypt stemness by controlling specific Wnt target genes (Schuijers2015Ascl2). ASCL2 is involved in various biological processes, including muscle regeneration and immune regulation, through its interactions with other proteins and DNA motifs (Mitkin2018Protective; Wang2016Ascl2). Clinically, ASCL2 is significant due to its altered expression in several cancers, such as colorectal and gastric cancers, where it contributes to tumor progression and metastasis (Zuo2018ASCL2; Jubb2006Achaetescute). Its role in cancer is further underscored by its impact on immune responses and the efficacy of immunotherapy (Wu2022ASCL2).

## Function
The ASCL2 gene encodes a basic helix-loop-helix (bHLH) transcription factor that plays a critical role in maintaining the stemness of intestinal stem cells. In healthy human cells, particularly within the intestinal epithelium, ASCL2 is expressed in a Wnt-dependent manner and acts as a master regulator of crypt stemness by controlling a specific subset of intestinal Wnt target genes (Schuijers2015Ascl2). ASCL2 forms an autoactivating loop, translating the Wnt gradient into a discrete transcriptional decision, which is crucial for the proliferation of epithelial crypt cells (Schuijers2015Ascl2).

ASCL2 functions as a bistable switch, capable of self-activation, allowing it to maintain two stable states: a stem-cell state (ASCL2-ON) and a non-stem-cell state (ASCL2-OFF). This autoactivation confers stability to the cell state and enables a binary interpretation of the Wnt signal gradient observed in the intestinal crypts (Schuijers2015Ascl2). ASCL2, together with β-catenin and TCF4, activates genes fundamental to the stem cell state, maintaining the Lgr5 stem cell phenotype robustly (Schuijers2015Ascl2). The presence of Wnt/R-spondin1 signaling is the principal driver of ASCL2 expression, and high levels of R-spondin1 can lead to hyperproliferation by surpassing the threshold for ASCL2 activation (Schuijers2015Ascl2).

## Clinical Significance
Alterations in the expression of the ASCL2 gene have been implicated in various cancers, particularly colorectal and gastric cancers. In colorectal cancer, ASCL2 is a target of Wnt signaling and is significantly upregulated in intestinal neoplasia, including adenomas and adenocarcinomas. This upregulation is associated with the regulation of the G2/M cell cycle checkpoint, promoting cell proliferation and potentially contributing to tumor progression (Jubb2006Achaetescute). ASCL2 is also overexpressed in colorectal cancer liver metastases with a gain in the 11p15.5 chromosomal region, suggesting its role in metastasis and stem cell-like properties of cancer cells (Stange2010Expression).

In gastric cancer, ASCL2 expression is higher in metastatic tissues compared to primary tumors and normal tissues. It promotes epithelial-mesenchymal transition (EMT), enhancing tumor cell migration and invasion. ASCL2 downregulates miR223, a microRNA that can reverse EMT, thereby facilitating metastasis (Zuo2018ASCL2).

ASCL2's role in cancer is further supported by its involvement in the regulation of immune responses in colon adenocarcinoma, where it affects the efficacy of immunotherapy by influencing immune cell infiltration and the WNT/b-catenin signaling pathway (Wu2022ASCL2).

## Interactions
ASCL2 interacts with various proteins and nucleic acids, playing a significant role in muscle regeneration and immune regulation. In muscle cells, ASCL2 inhibits myogenesis by interacting with E proteins such as E2-2/TCF4, HEB/TCF12, and E2A/TCF3. These interactions form inactive heterodimers with myogenic regulatory factors (MRFs) or compete with transcriptional coactivators, repressing the expression of myogenic factors like MyoD and Myog (Wang2016Ascl2). ASCL2 also binds directly to E-box DNA motifs, competing with MyoD for binding sites on the Myog promoter, which inhibits myogenic differentiation (Wang2016Ascl2).

In the context of immune regulation, ASCL2 interacts with the CD58 enhancer, particularly in the presence of the C allele of the SNP rs1335532, which creates a strong binding site for ASCL2. This interaction is associated with elevated CD58 expression in B-cells, influencing immune responses (Mitkin2018Protective). ASCL2's role in the Wnt/β-catenin signaling pathway further supports its involvement in B-cell activity, as it can induce the expression of CXCR5, a chemokine receptor important for B-cell migration (Mitkin2018Protective).


## References


[1. (Jubb2006Achaetescute) A M Jubb, S Chalasani, G D Frantz, R Smits, H I Grabsch, V Kavi, N J Maughan, K J Hillan, P Quirke, and H Koeppen. Achaete-scute like 2 (ascl2) is a target of wnt signalling and is upregulated in intestinal neoplasia. Oncogene, 25(24):3445–3457, March 2006. URL: http://dx.doi.org/10.1038/sj.onc.1209382, doi:10.1038/sj.onc.1209382. This article has 111 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1209382)

[2. (Zuo2018ASCL2) Qingsong Zuo, Jie Wang, Chao Chen, Yong Zhang, Dian‑Xu Feng, Ronghua Zhao, and Teng Chen. Ascl2 expression contributes to gastric tumor migration and invasion by downregulating mir223 and inducing emt. Molecular Medicine Reports, August 2018. URL: http://dx.doi.org/10.3892/mmr.2018.9363, doi:10.3892/mmr.2018.9363. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/mmr.2018.9363)

[3. (Mitkin2018Protective) Nikita A. Mitkin, Alisa M. Muratova, Kirill V. Korneev, Vsevolod V. Pavshintsev, Konstantin A. Rumyantsev, Murad S. Vagida, Aksinya N. Uvarova, Marina A. Afanasyeva, Anton M. Schwartz, and Dmitry V. Kuprash. Protective c allele of the single-nucleotide polymorphism rs1335532 is associated with strong binding of ascl2 transcription factor and elevated cd58 expression in b-cells. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1864(10):3211–3220, October 2018. URL: http://dx.doi.org/10.1016/j.bbadis.2018.07.008, doi:10.1016/j.bbadis.2018.07.008. This article has 15 citations.](https://doi.org/10.1016/j.bbadis.2018.07.008)

[4. (Schuijers2015Ascl2) Jurian Schuijers, Jan Philipp Junker, Michal Mokry, Pantelis Hatzis, Bon-Kyoung Koo, Valentina Sasselli, Laurens G. van der Flier, Edwin Cuppen, Alexander van Oudenaarden, and Hans Clevers. Ascl2 acts as an r-spondin/wnt-responsive switch to control stemness in intestinal crypts. Cell Stem Cell, 16(2):158–170, February 2015. URL: http://dx.doi.org/10.1016/j.stem.2014.12.006, doi:10.1016/j.stem.2014.12.006. This article has 216 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.stem.2014.12.006)

[5. (Stange2010Expression) D. E. Stange, F. Engel, T. Longerich, B. K. Koo, M. Koch, N. Delhomme, M. Aigner, G. Toedt, P. Schirmacher, P. Lichter, J. Weitz, and B. Radlwimmer. Expression of an ascl2 related stem cell signature and igf2 in colorectal cancer liver metastases with 11p15.5 gain. Gut, 59(9):1236–1244, May 2010. URL: http://dx.doi.org/10.1136/gut.2009.195701, doi:10.1136/gut.2009.195701. This article has 118 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1136/gut.2009.195701)

[6. (Wang2016Ascl2) Chao Wang, Min Wang, Justine Arrington, Tizhong Shan, Feng Yue, Yaohui Nie, Weiguo Andy Tao, and Shihuan Kuang. Ascl2 inhibits myogenesis by antagonizing the transcriptional activity of myogenic regulatory factors. Development, January 2016. URL: http://dx.doi.org/10.1242/dev.138099, doi:10.1242/dev.138099. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1242/dev.138099)

[7. (Wu2022ASCL2) Lei Wu, Shengnan Sun, Fei Qu, Xiuxiu Liu, Meili Sun, Ying Pan, Yan Zheng, and Guohai Su. Ascl2 affects the efficacy of immunotherapy in colon adenocarcinoma based on single-cell rna sequencing analysis. Frontiers in Immunology, June 2022. URL: http://dx.doi.org/10.3389/fimmu.2022.829640, doi:10.3389/fimmu.2022.829640. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2022.829640)